Diego Ambrogetti
Instituto de Investigaciones médicas Alfredo Lanari
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Diego Ambrogetti as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:25 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04036253 · Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney DiseaseBio Sidus SA · completed · Anemia of Chronic Kidney Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:25 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- DNA methylation-based biomarkers of aging were slowed down in a two-year diet and physical activity intervention trial: the DAMA study.Aging Cell · 2021166 citationsRCR 10.2
- Can Dietary and Physical Activity Modifications Reduce Breast Density in Postmenopausal Women? The DAMA Study, a Randomized Intervention Trial in Italy.Cancer Epidemiol Biomarkers Prev · 201921 citationsRCR 1.1
- 9 citationsRCR 0.4